                            NIH Public Access
                            Author Manuscript
                            Ann N Y Acad Sci. Author manuscript; available PMC 2006 17.
                           Published final edited form 
NIH-PA Author Manuscript




                            Ann N Y Acad Sci. 2005 November ; 1058: 105â€“118.


                           Development resistance RNAi mammalian cells

                           Zhi-Ming Zheng*, Shuang Tang, Mingfang Tao
                           HIV AIDS Malignancy Branch, Center Cancer Research, National Cancer Institute, National
                           Institutes Health, Bethesda, MD 20892, USA

                           Abstract
                                discovery RNA interference (RNAi) C. elegans plants revolutionized current
                                approaches biology medicine. RNAi silences genes sequence-specific manner                                 actions small pieces double-stranded RNAs (siRNAs miRNAs). RNAi                                 widespread natural phenomenon eukaryotic cells used powerful
                                experimental tool explore gene function. importantly, potential therapeutic
                                applications. Viral gene-specific siRNAs theoretically promising antiviral inhibitors                                 examined broad range medically important viruses.  RNA viruses
NIH-PA Author Manuscript




                                escape RNAi-mediated suppression counteracting RNAi machinery mutation                                 targeted region, encoding viral suppressors,  DNA viruses counteract RNAi
                                machinery, preferentially using viral suppressors. Cellular factors contribute RNAi
                                resistance; ADAR1 cellular factor responsible editing-mediated RNAi
                                resistance. siRNAs used potent small-molecule inhibitors cellular gene,                                 best way cell maintain expression essential genes long-term survival develop
                                program resist detrimental effects RNAi.


                           Keywords
                                RNA interference; siRNA; miRNA; gene expression; viral inhibitors; gene therapies


                           INTRODUCTION
                                            RNA interference (RNAi) recently recognized important mechanism                                             controlling gene expression post-transcriptional level19,49 regulating heterochromatin
                                            formation genome stability 54,69. RNAi-mediated post-transcriptional gene silencing NIH-PA Author Manuscript




                                            restrict expression certain genes tissue development cell differentiation. Small
                                            RNA duplexes, usually 21 23 nucleotides (nts) size, generated cleavage larger
                                            double-stranded (ds) RNAs ribonuclease Dicer 53,75. small RNA duplexes trigger
                                            RNAi sequence-specific cleavage degradation homologous single-stranded
                                            mRNA suppression mRNA translation 19,28,46.

                                            Based origin function, small RNAs produced Dicer cleavage classified
                                            categories: small interfering RNAs (siRNAs) microRNAs (miRNAs).                                             siRNAs miRNAs âˆ¼21- 23-bp duplexes bearing 2-nt overhangs 3â€² ends.                                             differ siRNAs originate cytoplasm cleavage long dsRNAs perfect
                                            base-pairing26,73, miRNAs derived cleavage long, single-stranded
                                            primary transcripts containing imperfectly matched hairpin-loop structures. general, primary
                                            miRNA transcripts cleaved RNase III-like protein Drosha âˆ¼65 nt stem-


                           *Corresponding author: HIV AIDS Malignancy Branch, Center Cancer Research, National Cancer Institute, National Institutes
                           Health, 10 Center Dr., Rm. 10S 255, Bethesda, MD 20892, USA, Tel. 301-594-1382, Fax: 301-480-8250, email:
                           zhengt@exchange.nih.gov
                            Zheng et al.                                                                                               Page 2


                                          loop pre-miRNAs nucleoplasm34,35 transported Exportin-5                                           cytoplasm 44, processed Dicer âˆ¼21- 23-bp miRNA duplexes
                                          imperfect base-pairing. siRNAs miRNAs, strand (antisense) NIH-PA Author Manuscript




                                          selectively incorporated dsRNA-induced silencing complex (RISC) contains
                                          Argonaute (eIF2C), SMN3, proteins 27,46,47 guides selection                                           complementary mRNA cleavage translational inhibition. Recently, Ago 2 shown
                                          key component cleavage substrate 27,55. accumulated evidence far
                                          indicates siRNAs miRNAs program RISCs equivalently produce similar
                                          effects mRNA expression despite somewhat different origins 16,74.

                                          RNAi induced introduction synthetic âˆ¼21- 23-nt siRNA duplexes cells,
                                          bypassing requirement processing long dsRNA mediated Dicer 20. RNAi
                                          mediated siRNAs miRNAs artificially introduced mammalian cells                                           successfully used knock gene expression suppress viral replication,                                           outcome individual RNAi events varies depending designed siRNAs                                           targeted regions. Efficient silencing target using RNAi approach requires active
                                          cell metabolism, cells undergoing exponential growth. transient transfection
                                          assays synthetic siRNA duplexes, run RNAi effective dose generally confers
                                          detectable suppression target 48-72 hours (Fig. 1). runs                                           RNAi needed achieve extensive longer-lasting suppression.                                           individual siRNAâ€™s half-life targeted region influence proficiency RNAi, active
NIH-PA Author Manuscript




                                          RISC function cells necessary make suppression effective. Cells                                           exponentially active growth confer efficient siRNA duplexes active
                                          RISC function. shown Fig. 1, cells 96 hours culture response RNAi
                                          (compare lane 7 lane 6) affected siRNA-mediated p53 suppression.
                                          â€œRNAi resistanceâ€? usually refers active processes, discussed  care
                                          taken study RNAi RNAi resistance cells appropriate phase growth.

                                          known plant virology plant viruses                                           counteract RNAi plant cells order invade hosts, reports                                           development RNAi resistance mammalian cells came surprise. Approximately 22
                                          silencing suppressors described plant insect viruses;                                           summarized excellent reviews 15,38,68,72. report, emphasize                                           emergence siRNA resistance mechanism counteracts RNAi-mediated gene
                                          silencing mammalian cells (Table 1).

                              Development resistance siRNA-mediated viral gene silencing RNA
                              virus infections
NIH-PA Author Manuscript




                                          RNA viruses RNA genome single-stranded double-stranded. Viral
                                          RNA replication infected cells mediated viral RNA-dependent RNA polymerase
                                          (RDRP), produces dsRNA intermediate phase single-stranded RNA viruses.
                                          lacks proofreading activity, viral RDRP replicates RNA genome low
                                          fidelity, resulting mutation rate order âˆ¼10-4 incorporated nucleotide. 
                                          viral RDRP inherent error frequency order 1 104, depending virus
                                          17,36.  conceivable RNA viruses selection pressure escape siRNA-
                                          mediated suppression mutation target regions, siRNA-resistant
                                          viruses. presumption supported accumulating evidence elegant
                                          studies, described 

                                          Using RNAi antiviral therapy considered viruses, including DNA
                                          viruses RNA viruses. Poliovirus tested siRNA-mediated
                                          sequence-specific inhibition. HeLa cells treated siRNA specific capsid protein 

                                             Ann N Y Acad Sci. Author manuscript; available PMC 2006 17.
                            Zheng et al.                                                                                             Page 3


                                          viral polymerase infection virulent poliovirus produced 1 -3  virus
                                          titer observed control-treated cells showed virus plaque formation.                                            poliovirus readily escapes highly effective siRNAs unique point mutations NIH-PA Author Manuscript




                                          targeted regions 23. emergence siRNA-resistant viruses begins 30-40 hours
                                          postinfection. analysis resistant mutants showed RNAi recognition                                           sensitive subtle point mutations central region 3â€² end target RNA.
                                          single point mutation resulting G:U mismatch sufficient virus escape
                                          siRNA inhibition 24. Using pool siRNAs simultaneously target multiple sites                                           virus genome good choice prevent emergence resistant viruses.

                                          RNAi demonstrated powerful tool suppressing HIV infection various
                                          transient, short-term assays 11,29â€‰33,48. Recently, resistance RNAi directed HIV-1
                                          noticed siRNA duplexes targeting viral tat 1 nef 12 genes stably
                                          expressed human T cells long-term inhibition. RNAi-resistant HIV-1 variants                                           identified deletions substitutions siRNA target regions. mutations,
                                          HIV-1 removes RNA target escapes RNAi-mediated inhibition.

                                          Resistance siRNA-mediated suppression La Crosse Virus (LACV) replication                                           noticed 72 hours virus infection 293T cells pre-treated LACV siRNAs
                                          61. resistant viruses recovered culture supernatant single double
                                          nucleotide changes targeted regions, significantly high frequency portion
NIH-PA Author Manuscript




                                          S segment targeted siRNA LACS103. interestingly, viral nonstructural
                                          protein LACV, NSs, appears function RNAi suppressor protein. Cells expressing
                                          NSs protein strongly suppress RNAi directed LACV M segment host
                                          gene, GAPDH (glyeraldehyde-3-phosphate dehydrogenase) 61.

                                          Tas protein retrovirus primate foamy virus type 1 (PFV-1) recently                                           identified suppressor miR-32, miRNA cellular origin. PFV-1 open reading
                                          frame 2 contains target miR-32. counterdefense miR-32-mediated suppression,
                                          PFV-1 encodes Tas silencing suppressor enables host cell invasion virus
                                          replication 32.

                              Development resistance siRNA-mediated viral gene silencing DNA
                              virus infections
                                          Compared RNA viruses, designed high rate mutation                                           RNA genome replication, genomes DNA viruses relatively stable, low
                                          mutation rate 10-8 10-11 incorporated nucleotide.  resistance RNAi-mediated
                                          viral gene silencing mutation target sequence observed DNA
NIH-PA Author Manuscript




                                          virus infection.  siRNA exert selection pressure pre-existing resistant
                                          mutants, exemplified recent report hepatitis B virus (HBV) 70. HBV DNA virus,
                                          DNA replicates genomic RNA intermediate utilizes virally encoded
                                          reverse transcriptase. Consequently, significant diversity, similar seen                                           RNA viruses, occurs sequences HBV isolates; classified 8
                                          genotypes  H). mutant C genotype contains mutation 3â€² portion targeted
                                          region isolated resistant HBVS1 short hairpin (sh) RNA-mediated RNAi
                                          wild-type. mutant preferentially selected presence HBVS1
                                          shRNA Huh-7 cells transfected wild-type mutant HBV-C ratio 9:1 day
                                          5 post-transfection 70.

                                          Adenovirus infection result inhibition RNAi, actions                                           virally encoded noncoding RNA, VA1. Adenovirus VA1 RNA âˆ¼160-nt structured RNA
                                          highly expressed adenovirus-infected cells (âˆ¼108 molecules/cell) plays important


                                             Ann N Y Acad Sci. Author manuscript; available PMC 2006 17.
                            Zheng et al.                                                                                               Page 4


                                          roles increasing viral mRNA translation 65 stabilizing ribosome-bound mRNAs 63,
                                          64. VA1 RNA enhances viral mRNA translation blocking activation protein kinase R
                                          (PKR), usually induced viral dsRNA produced adenoviral replication
NIH-PA Author Manuscript




                                          cycle. Cullen colleagues recently used reporter assay VA1 RNA inhibits
                                          RNAi induced shRNAs, does affect RNAi induced synthetic siRNA duplexes.
                                          VA1 RNA-mediated inhibition RNAi appears occur inhibition nuclear export
                                          shRNA, competition Exportin-5, inhibition Dicer function direct binding                                           Dicer 43.

                                          recent study shRNA-mediated oncogene silencing human papillomavirus 16
                                          (HPV16) cervical cancer cells provides evidence DNA virus escape RNAi
                                          (Tang, S., et al., unpublished data). HPV16 contains viral oncogenes encode E6,                                           targets p53 degradation, E7, targets pRB. oncogenes transcribed                                           single E6E7 bicistronic RNA essential genes survival cervical cancer cells.
                                          Transfection HPV16-positive cervical cancer cell lines, CaSki SiHa, synthetic
                                          siRNA duplex based sequence motif 21 nts HPV16 E6E7 bicistronic RNA
                                          effectively suppressed E6 E7 oncogenes, leading stabilization p53                                           increased p21 expression. stably expressed short hairpin RNA cells                                           selection pressure,  siRNA silencing E6 E7 expression efficient                                           early cell passages, inefficient additional cell passages despite continued
                                          expression siRNA level. loss siRNA function duplicated NIH-PA Author Manuscript




                                          cells stable p53 siRNA, cells stable lamin C siRNA, suggesting                                           target-selective. siRNA-resistant cells retain normal siRNA processing, duplex
                                          unwinding degradation unwound sense strand, RISC formation, suggesting                                           loss siRNA function occurred later step. Surprisingly, siRNA-resistant cells                                           contain cytoplasmic protein âˆ¼50 kDa specifically characteristically
                                          interacted E6E7 siRNA. data indicate potent siRNA targeting essential
                                          regulatory gene induce cell develop siRNA resistance production                                           specific protein.

                              Viral proteins mammalian viruses function suppressors RNAi                               non-mammalian cells plants
                                          viral proteins expressed mammalian viruses, interferon antagonist proteins
                                          influenza virus NS1 (non-structural protein 1), reovirus Ïƒ3, vaccinia virus E3L,                                           examined suppressive effects RNAi non-mammalian cells.

                                          Influenza viruses group single-stranded RNA viruses divided types  B,
                                          C. influenza virus NS1 protein multifunctional, non-structural protein contains
NIH-PA Author Manuscript




                                          functional domains. domains N-terminal half NS1:                                           responsible translational enhancement influenza virus mRNAs interactions
                                          eIF4G, eukaryotic translation initiation factor, essential dsRNA-
                                          binding antagonizing interferon induction sequestering dsRNA PKR binding                                           activation. domain, inhibits mRNA processing nuclear-cytoplasmic
                                          transport host mRNAs, C-terminal half protein 31. Using plant silencing
                                          suppression assay, groups simultaneously demonstrated influenza NS1 protein                                           RNA silencing suppressor plants promotes plant virus pathogenicity potato virus
                                          X different plant hosts 3,14. NS1 suppression RNAi requires dsRNA-binding
                                          domain protein functional interact siRNAs 3. observations
                                          supported independent evidence Ding Palese groups showing                                           NS1 proteins influenza  B, C viruses RNAi suppressors                                           Drosophila cell-based, nodaviral silencing screen assay. study showed NS1 


                                             Ann N Y Acad Sci. Author manuscript; available PMC 2006 17.
                            Zheng et al.                                                                                            Page 5


                                          influenza viruses suppresses RNAi Drosophila cells N-terminal dsRNA-
                                          binding domain binding siRNAs 39.
NIH-PA Author Manuscript




                                          Reoviruses group dsRNA viruses. Reovirus outer shell polypeptide Ïƒ3                                           best-characterized dsRNA binding proteins. Like influenza virus NS1, reovirus Ïƒ3 carries
                                          conserved dsRNA-binding motifs binds dsRNAs vitro vivo. Accordingly,
                                          reovirus Ïƒ3 protein sequesters dsRNA PKR binding prevents activation                                           dsRNA. tested plant cells, Ïƒ3 showed strong RNAi suppression, failed                                           sequester miRNA precursors 40.  data suggest reovirus Ïƒ3 protein                                           capable counteracting RNAi-mediated gene silencing addition inhibiting PKR-
                                          mediated responses.

                                          Vaccinia virus member poxvirus family DNA genome replicates                                           cytoplasm viral infection. vaccinia E3L protein dsRNA-binding protein
                                          13 inhibits PKR sequestering dsRNA PKR, preventing binding 56,59.                                           C-terminus vaccinia virus E3L responsible binding dsRNA preventing                                           activating interferon pathway. recent study demonstrated E3L protein                                           functional suppressor RNAi Drosophila cells inactivates RNAi silencing-based
                                          antiviral response cells flock house virus infection 39.

                              RNA editing plays role development siRNA resistance NIH-PA Author Manuscript




                              mammalian cells
                                          Double-stranded RNA induces homology-dependent degradation cognate mRNA                                           cytoplasm RNAi, target adenosine inosine   RNA editing                                           adenosine deaminases acting RNA (ADARs). RNA editing affects siRNA-mediated
                                          RNAi vitro reported Chris Smithâ€™s group 58, showed production                                           siRNAs progressively inhibited increasing deamination long dsRNA.                                           initial observation immediately supported study C. elegans showed 
                                          editing dsRNAs derived transgenes endogenous genes appeared                                           prevent silencing RNAi 30,67. Recent studies demonstrated direct interaction
                                          isoforms ADARs siRNA,  ADAR1 ADAR2, strongly
                                          bind siRNA RNA editing. ADAR1p110, short form ADAR1 alternative
                                          translation initiation codon, ADAR2 bound 19-bp siRNA, binding affinities
                                          15 50 times lower ADAR1p150  length ADAR1), respectively.
                                          ADAR3 bound longer dsRNAs, failed bind 19-bp siRNA. ADARs                                           capable binding 19-bp siRNA (ADAR1p150 p110 ADAR2) bound siRNAs
                                          containing 15- 23-bp dsRNA regions.  length siRNA determines
                                          bound siRNA edited held stable complex change sequence;
NIH-PA Author Manuscript




                                          critical size threshold appears 30 bp 71.

                                          cytoplasmic length isoform ADAR1 highest affinity siRNA                                           known ADARs, subnanomolar dissociation constant. Gene silencing siRNA                                           significantly effective mouse fibroblasts homozygous ADAR1 null mutation
                                          wild-type cells. supported suppression RNAi fibroblast
                                          cells overexpressing functional ADAR1, cells overexpressing mutant ADAR1
                                          lacking double-stranded RNA-binding domains. results provide convincing evidence                                           ADAR1 cellular factor limits efficacy siRNA mammalian cells 71.

                              factors lead RNAi resistance mammalian cells
                                          described  resistance RNAi viral infection mammalian cells far
                                          ascribed major mechanisms: mutations targeted regions expression 

                                             Ann N Y Acad Sci. Author manuscript; available PMC 2006 17.
                            Zheng et al.                                                                                               Page 6


                                          suppressors (Table 1). wonder viruses evolved mechanism(s)                                           counteract initiation RNAi pathway, block pathwayâ€™s intermediate
                                          components.
NIH-PA Author Manuscript




                                          hypothesis received preliminary support hepatitis delta virus (HDV)
                                          study. Data Taylorâ€™s group indicate HDV RNAs resistant Dicer activity 7.
                                          Dicer cleaves RNAs 100  double-stranded, certain RNAs extensive
                                          <100  pairing, release RNAs âˆ¼21 nt. circular 1,679-nt genome HDV                                           exact complement, antigenomic RNA, fold rod-like structure 74  pairing,
                                          resistance Dicer cleavage. vitro cleavage assay purified recombinant
                                          Dicer, <0.2  unit-length HDV RNAs cleaved, Dicer able digest
                                          fragments genome. 66-nt hairpin RNA 79  pairing digested >80 
                                          cleavage activity, 66-nt hairpin derived end HDV genome                                           digested. data vitro Dicer digestion experiments consistent results
                                          small RNAs âˆ¼21 nts detected HDV replication hepatocytes 7.                                           unit-length, highly structured HDV RNAs resist Dicer cleavage suggests viral RNAs
                                          evolved prevent initiation RNAi resisting Dicer. HDV itself                                           edited ADAR adenosine 1012 position antigenome 6,52, resistance Dicer                                           RNAi appears unrelated ADAR-mediated editing.

                                          group 1,679-nt genomic antigenomic RNAs HDV NIH-PA Author Manuscript




                                          resistant siRNA-mediated degradation, viral mRNAs sensitive synthetic
                                          siRNA duplexes. thought base-paring HDV genomic antigenomic RNAs
                                          nucleus make inaccessible siRNA.  studies                                           HDV circular RNAs transcribed DNA template host RNA polymerase II                                           Huh-7 cells, similar mRNA structure mRNAs 5â€² cap 3â€² poly                                           tail, resistant siRNA attack 8. mechanism HDV resistant
                                          siRNA remains unknown.

                              Does siRNA activate protein kinase PKR?
                                          PKR, mammalian dsRNA-dependent serine-threonine protein kinase, N-terminal
                                          dsRNA-binding domain interact non-sequence-specifically long stretches                                           dsRNA, leading activation. activated PKR phosphorylates inactivates translation
                                          factor eIF2â€œ, resulting generalized suppression protein synthesis, followed cell death
                                          apoptotic nonapoptotic pathways. Activation nonspecific pathway                                           mask sequence-specific effects result RNAi pathway. 
                                          successful application RNAi reported mammalian tissue culture cell lines
                                          using chemically synthesized siRNAs bypass activation PKR. NIH-PA Author Manuscript




                                          documented literature small blunt-ended dsRNA 33 bp does activate
                                          PKR 45. addition, early studies demonstrated siRNA-mediated inhibition gene
                                          expression mammalian cells independent non-specific interference pathways activated
                                          larger dsRNAs 5.  recent studies indicate  RNAi mechanism
                                          itself independent interferon  transfection 21-bp siRNAs expression                                           shRNAs shRNA vectors does trigger interferon response PKR 2,60. 
                                          studies argue siRNAs broad complicating effects selective
                                          silencing target genes introduced cells.

                                          effort evaluate contradictory results search possible activators PKR,
                                          truncated length versions PKR used select dsRNAs partially
                                          structured dsRNA library containing 1011 sequences 76. study identified minimal RNA
                                          motif activation PKR. motif hairpin nonconserved, imperfect 16-bp
                                          dsRNA stem flanked 11- 15-nt single-stranded tails. Boundary experiments revealed 

                                             Ann N Y Acad Sci. Author manuscript; available PMC 2006 17.
                            Zheng et al.                                                                                                Page 7


                                          single-stranded tails flanking dsRNA core provide critical determinant                                           activation. minimum 11 nts tails needed activation, tails                                           5â€²-end, 3â€²-end, 76. group compared dsRNAs lengths 24,
NIH-PA Author Manuscript




                                          33, 76 bp PKR binding activation 24-bp dsRNA unable                                           activate PKR; instead, inhibited kinase. Resolution discrepancies                                           findings different study groups require additional biochemical experiments.

                              Closing remarks perspectives
                                          entering RNAi era. discovery RNAi C. elegans 21 plants 25                                           revolutionized todayâ€™s approaches biology medicine. actions small
                                          pieces dsRNAs (siRNAs miRNAs), RNAi-mediated gene silencing                                           widespread natural phenomenon eukaryotes, powerful experimental
                                          tool explore gene function. importantly, potential therapeutic applications.
                                          great deal learned past years RNAi pathways                                           functions components, remains understood complete
                                          picture RNAi regulated mammalian cells. absolutely doubt RNAi
                                          pathways, just like pathways discovered mammalian systems, subject                                           sophisticated regulation (Fig. 2).

                                          RNAi function mammalian cells thought nucleic acid-based antiviral
NIH-PA Author Manuscript




                                          immunity, evidenced recent discovery cellular miR-32 mediates antiviral
                                          activities human cells 32. Identification viral RNAi suppressors medically important
                                          RNA DNA viruses heralded beginning exploration existing anti-silencing
                                          mechanisms virus infection. RNAi suppressors identified far various RNAi
                                          reporter assays turn viral dsRNA binding proteins (DRBPs). fewer cellular
                                          DRBPs identified viral DRBPs, assume regulate
                                          endogenous miRNA siRNA functions cell needed. 300 miRNAs
                                          identified genomes humans, viruses, non-human eukaryotic species,
                                          abundant (âˆ¼ 40,000 copies/cell) 4,41,42,50,51. question                                           examine DRBPâ€™s suppressive function mammalian  suppressive functions
                                          viral RNA suppressors RNAi reporter assays recapitulated vivo
                                          viral infections mammals. example, NS1 Influenza virus behaves effective
                                          RNAi suppressor Drosophila plant RNAi reporters, play role                                           siRNA-mediated inhibition animal influenza infection 22,66.

                                          388 known eukaryotic proteins dsRNA-binding domains (DRBDs), 72
                                          human 37,62. 20 DRBPs identified reported                                           function diverse range critically important roles cell, including                                            Dicer Ago-2) essential roles RNAi pathways 18,57. proteins harboring
NIH-PA Author Manuscript




                                          DRBDs reported interact little 11 bp dsRNA, event                                           independent nucleotide sequence arrangement 57, conceivable cellular
                                          DRBPs actually involved switching function partially double-
                                          stranded miRNA  average, targets hundreds mRNAs pairing                                           6-8 bases. ADAR1 factor type interacts siRNAs vitro limits
                                          efficacy siRNAs mammalian cells.

                                          intriguing question natural siRNA eukaryotic
                                          cells virus infection. RNA viruses dsRNA genome                                           carry single-stranded RNA genome, produce dsRNA intermediates                                           replication. Theoretically, viral dsRNAs substrates Dicer digestion                                           produce siRNAs infected cells.  viral dsRNAs appear resist Dicer digestion,
                                          exemplified HDV. production viral siRNAs suppress viral


                                             Ann N Y Acad Sci. Author manuscript; available PMC 2006 17.
                            Zheng et al.                                                                                                   Page 8


                                          gene expression harmful replication virus. Similarly, endogenous siRNA
                                          production human genome expected, considering 20  human
                                          genes produce antisense transcripts form sense-antisense pairs (dsRNA) 9, NIH-PA Author Manuscript




                                          production endogenous siRNAs human transcripts beneficial                                           human gene expression. Discovering dsRNAs escape Dicer digestion                                           challenge.

                                          Understanding viral RNAi resistance greatly enriched knowledge regulation                                           RNAi pathways. greatly informative know viruses escape RNAi-
                                          mediated inhibition counteracting mechanisms: mutations targeted
                                          region siRNA selection pressure production RNAi suppressors. 
                                          HPV16 use method develop siRNA resistance, proteins                                           appear involved siRNA resistance cells expressing HPV16 E6 E7                                           viral proteins ADAR1. Identification characterization proteins                                           extremely challenging, definitely guide understanding cell
                                          counteracts siRNA-mediated events adversely affect survival. siRNAs
                                          used potent small-molecule inhibitors cellular gene, best way cell                                           expression genes essential survival develop program                                           resist detrimental effects RNAi.

                              Reference List
NIH-PA Author Manuscript




                                          1. Boden D, Pusch O, Lee F, Tucker L, Ramratnam B. Human immunodeficiency virus type 1 escape
                                             RNA interference. J. Virol 2003;77:11531â€“11535. [PubMed: 14557638]
                                          2. Bridge AJ, Pebernard S, Ducraux  Nicoulaz AL, Iggo R. Induction interferon response                                              RNAi vectors mammalian cells. Nat. Genet 2003;34:263â€“264. [PubMed: 12796781]
                                          3. Bucher E, Hemmes H, Haan P, Goldbach R, Prins M. influenza virus NS1 protein binds
                                             small interfering RNAs suppresses RNA silencing plants. J. Gen. Virol 2004;85:983â€“991.
                                             [PubMed: 15039540]
                                          4. Cai X, Lu S, Zhang  Gonzalez CM, Damania B, Cullen BR. Kaposiâ€™s sarcoma-associated herpesvirus
                                             expresses array viral microRNAs latently infected cells. Proc. Natl. Acad. Sci. U. S.                                              2005;102:5570â€“5575. [PubMed: 15800047]
                                          5. Caplen NJ, Parrish S, Imani F,  Morgan RA. Specific inhibition gene expression small
                                             double-stranded RNAs invertebrate vertebrate systems. Proc. Natl. Acad. Sci. U. S.                                              2001;98:9742â€“9747. [PubMed: 11481446]
                                          6. Casey JL, Gerin JL. Hepatitis D virus RNA editing: specific modification adenosine                                              antigenomic RNA. J. Virol 1995;69:7593â€“7600. [PubMed: 7494266]
                                          7. Chang J, Provost P, Taylor JM. Resistance human hepatitis delta virus RNAs dicer activity. J.
                                             Virol 2003;77:11910â€“11917. [PubMed: 14581527]
NIH-PA Author Manuscript




                                          8. Chang J, Taylor JM. Susceptibility human hepatitis delta virus RNAs small interfering RNA
                                             action. J. Virol 2003;77:9728â€“9731. [PubMed: 12915586]
                                          9. Chen J, Sun M, Kent WJ, Huang X, Xie H, Wang W, Zhou G, Shi RZ, Rowley JD. 20  human
                                             transcripts form sense-antisense pairs. Nucleic Acids Res 2004;32:4812â€“4820. [PubMed:
                                             15356298]
                                          10. Child SJ, Hakki M, Niro KL, Geballe AP. Evasion cellular antiviral responses human
                                               cytomegalovirus TRS1 IRS1. J. Virol 2004;78:197â€“205. [PubMed: 14671101]
                                          11. Coburn GA, Cullen BR. Potent specific inhibition human immunodeficiency virus type 1
                                               replication RNA interference. J. Virol 2002;76:9225â€“9231. [PubMed: 12186906]
                                          12. Das  Brummelkamp TR, Westerhout EM, Vink M, Madiredjo M, Bernards R, Berkhout B. Human
                                               immunodeficiency virus type 1 escapes RNA interference-mediated inhibition. J. Virol
                                               2004;78:2601â€“2605. [PubMed: 14963165]
                                          13. Davies MV, Chang HW, Jacobs BL, Kaufman RJ. E3L K3L vaccinia virus gene products
                                               stimulate translation inhibition double-stranded RNA-dependent protein kinase                                                different mechanisms. J. Virol 1993;67:1688â€“1692. [PubMed: 8094759]


                                              Ann N Y Acad Sci. Author manuscript; available PMC 2006 17.
                            Zheng et al.                                                                                                    Page 9


                                          14. Delgadillo MO, Saenz P, Salvador B, Garcia JA, Simon-Mateo C. Human influenza virus NS1 protein
                                              enhances viral pathogenicity acts RNA silencing suppressor plants. J. Gen. Virol
                                              2004;85:993â€“999. [PubMed: 15039541]
NIH-PA Author Manuscript




                                          15. Ding SW, Li H, Lu R, Li F, Li WX. RNA silencing: conserved antiviral immunity plants                                               animals. Virus Res 2004;102:109â€“115. [PubMed: 15068886]
                                          16. Doench JG, Petersen CP, Sharp PA. siRNAs function miRNAs. Genes Dev 2003;17:438â€“442.
                                              [PubMed: 12600936]
                                          17. Dougherty JP, Temin HM. Determination rate base-pair substitution insertion mutations
                                              retrovirus replication. J. Virol 1988;62:2817â€“2822. [PubMed: 2839703]
                                          18. Doyle M, Jantsch MF. New old roles double-stranded RNA-binding domain. J. Struct. Biol
                                              2002;140:147â€“153. [PubMed: 12490163]
                                          19. Dykxhoorn DM, Novina CD, Sharp PA. Killing messenger: short RNAs silence gene
                                              expression. Nat. Rev. Mol. Cell Biol 2003;4:457â€“467. [PubMed: 12778125]
                                          20. Elbashir SM, Harborth J, Lendeckel W, Yalcin  Weber K, Tuschl T. Duplexes 21-nucleotide
                                              RNAs mediate RNA interference cultured mammalian cells. Nature 2001;411:494â€“498. [PubMed:
                                              11373684]
                                          21.  Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent specific genetic
                                              interference double-stranded RNA Caenorhabditis elegans. Nature 1998;391:806â€“811.
                                              [PubMed: 9486653]
                                          22. Ge Q, Filip L, Bai  Nguyen T, Eisen HN, Chen J. Inhibition influenza virus production virus-
                                              infected mice RNA interference. Proc. Natl. Acad. Sci. U. S. 2004;101:8676â€“8681. [PubMed:
NIH-PA Author Manuscript




                                              15173599]
                                          23. Gitlin L, Karelsky S, Andino R. Short interfering RNA confers intracellular antiviral immunity                                               human cells. Nature 2002;418:430â€“434. [PubMed: 12087357]
                                          24. Gitlin L, Stone JK, Andino R. Poliovirus escape RNA interference: short interfering RNA-target
                                              recognition implications therapeutic approaches. J. Virol 2005;79:1027â€“1035. [PubMed:
                                              15613331]
                                          25. Hamilton AJ, Baulcombe DC. species small antisense RNA posttranscriptional gene silencing
                                              plants. Science 1999;286:950â€“952. [PubMed: 10542148]
                                          26. Hammond SM, Bernstein E, Beach D, Hannon GJ. RNA-directed nuclease mediates post-
                                              transcriptional gene silencing Drosophila cells. Nature 2000;404:293â€“296. [PubMed: 10749213]
                                          27. Hammond SM, Boettcher S, Caudy AA, Kobayashi R, Hannon GJ. Argonaute2, link genetic
                                              biochemical analyses RNAi. Science 2001;293:1146â€“1150. [PubMed: 11498593]
                                          28. Hannon GJ. RNA interference. Nature 2002;418:244â€“251. [PubMed: 12110901]
                                          29. Jacque JM, Triques K, Stevenson M. Modulation HIV-1 replication RNA interference. Nature
                                              2002;418:435â€“438. [PubMed: 12087358]
                                          30. Knight SW, Bass BL. role RNA editing ADARs RNAi. Mol. Cell 2002;10:809â€“817.
                                              [PubMed: 12419225]
                                          31. Krug RM, Yuan W, Noah DL, Latham AG. Intracellular warfare human influenza viruses
NIH-PA Author Manuscript




                                              human cells: roles viral NS1 protein. Virology 2003;309:181â€“189. [PubMed:
                                              12758165]
                                          32. Lecellier CH, Dunoyer P, Arar K, Lehmann-Che J, Eyquem S, Himber C, Saib  Voinnet O.                                               cellular microRNA mediates antiviral defense human cells. Science 2005;308:557â€“560. [PubMed:
                                              15845854]
                                          33. Lee NS, Dohjima T, Bauer G, Li H, Li MJ, Ehsani  Salvaterra P, Rossi J. Expression small
                                              interfering RNAs targeted HIV-1 rev transcripts human cells. Nat. Biotechnol
                                              2002;20:500â€“505. [PubMed: 11981565]
                                          34. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, Kim VN.                                               nuclear RNase III Drosha initiates microRNA processing. Nature 2003;425:415â€“419. [PubMed:
                                              14508493]
                                          35. Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise processing subcellular
                                              localization. EMBO J 2002;21:4663â€“4670. [PubMed: 12198168]




                                              Ann N Y Acad Sci. Author manuscript; available PMC 2006 17.
                            Zheng et al.                                                                                                    Page 10


                                          36. Leider JM, Palese P, Smith FI. Determination mutation rate retrovirus. J. Virol
                                              1988;62:3084â€“3091. [PubMed: 2841464]
                                          37. Letunic  Copley RR, Schmidt S, Ciccarelli FD, Doerks T, Schultz J, Ponting CP, Bork P. SMART
NIH-PA Author Manuscript




                                              4.0: genomic data integration. Nucleic Acids Res 2004;32:D142â€“D144. [PubMed:
                                              14681379]
                                          38. Li WX, Ding SW. Viral suppressors RNA silencing. Curr. Opin. Biotechnol 2001;12:150â€“154.
                                              [PubMed: 11287229]
                                          39. Li WX, Li H, Lu R, Li F, Dus M, Atkinson P, Brydon EW, Johnson KL, Garcia-Sastre  Ball LA,
                                              Palese P, Ding SW. Interferon antagonist proteins influenza vaccinia viruses suppressors
                                              RNA silencing. Proc. Natl. Acad. Sci. U. S. 2004;101:1350â€“1355. [PubMed: 14745017]
                                          40. Lichner  Silhavy D, Burgyan J. Double-stranded RNA-binding proteins suppress RNA
                                              interference-mediated antiviral defences. J. Gen. Virol 2003;84:975â€“980. [PubMed: 12655099]
                                          41. Lim LP, Glasner  Yekta S, Burge CB, Bartel DP. Vertebrate microRNA genes. Science
                                              2003;299:1540. [PubMed: 12624257]
                                          42. Lim LP, Lau NC, Weinstein  Abdelhakim  Yekta S, Rhoades MW, Burge CB, Bartel DP.                                               microRNAs Caenorhabditis elegans. Genes Dev 2003;17:991â€“1008. [PubMed: 12672692]
                                          43. Lu S, Cullen BR. Adenovirus VA1 noncoding RNA inhibit small interfering RNA MicroRNA
                                              biogenesis. J. Virol 2004;78:12868â€“12876. [PubMed: 15542639]
                                          44. Lund E, Guttinger S, Calado  Dahlberg JE, Kutay U. Nuclear export microRNA precursors.
                                              Science 2004;303:95â€“98. [PubMed: 14631048]
                                          45. Manche L, Green SR, Schmedt C, Mathews MB. Interactions double-stranded RNA
NIH-PA Author Manuscript




                                              regulators protein kinase DAI. Mol. Cell Biol 1992;12:5238â€“5248. [PubMed: 1357546]
                                          46. Martinez J, Patkaniowska  Urlaub H, Luhrmann R, Tuschl T. Single-stranded antisense siRNAs
                                              guide target RNA cleavage RNAi. Cell 2002;110:563â€“574. [PubMed: 12230974]
                                          47. Mourelatos  Dostie J, Paushkin S, Sharma  Charroux B, Abel L, Rappsilber J, Mann M, Dreyfuss
                                              G. miRNPs: novel class ribonucleoproteins containing numerous microRNAs. Genes Dev
                                              2002;16:720â€“728. [PubMed: 11914277]
                                          48. Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK, Collman RG, Lieberman
                                              J, Shankar P, Sharp PA. siRNA-directed inhibition HIV-1 infection. Nat. Med 2002;8:681â€“686.
                                              [PubMed: 12042777]
                                          49. Novina CD, Sharp PA. RNAi revolution. Nature 2004;430:161â€“164. [PubMed: 15241403]
                                          50. Pfeffer S, Sewer  Lagos-Quintana M, Sheridan R, Sander C, Grasser FA, van Dyk LF, Ho CK,
                                              Shuman S, Chien M, Russo JJ, Ju J, Randall G, Lindenbach BD, Rice CM, Simon V, Ho DD, Zavolan
                                              M, Tuschl T. Identification microRNAs herpesvirus family. Nat. Methods 2005;2:269â€“276.
                                              [PubMed: 15782219]
                                          51. Pfeffer S, Zavolan M, Grasser FA, Chien M, Russo JJ, Ju J, John B, Enright AJ, Marks D, Sander C,
                                              Tuschl T. Identification virus-encoded microRNAs. Science 2004;304:734â€“736. [PubMed:
                                              15118162]
                                          52. Polson AG, Bass BL, Casey JL. RNA editing hepatitis delta virus antigenome dsRNA-adenosine
NIH-PA Author Manuscript




                                              deaminase. Nature 1996;380:454â€“456. [PubMed: 8602246]
                                          53. Provost P, Dishart D, Doucet J, Frendewey D, Samuelsson B, Radmark O. Ribonuclease activity                                               RNA binding recombinant human Dicer. EMBO J 2002;21:5864â€“5874. [PubMed: 12411504]
                                          54. Provost P, Silverstein RA, Dishart D, Walfridsson J, Djupedal  Kniola B, Wright  Samuelsson B,
                                              Radmark O, Ekwall K. Dicer required chromosome segregation gene silencing fission
                                              yeast cells. Proc. Natl. Acad. Sci. U. S. 2002;99:16648â€“16653. [PubMed: 12482946]
                                          55. Rand TA, Ginalski K, Grishin NV, Wang X. Biochemical identification Argonaute 2 sole
                                              protein required RNA-induced silencing complex activity. Proc. Natl. Acad. Sci. U. S.                                               2004;101:14385â€“14389. [PubMed: 15452342]
                                          56. Romano PR, Zhang F, Tan SL, Garcia-Barrio MT, Katze MG, Dever TE, Hinnebusch AG. Inhibition
                                              double-stranded RNA-dependent protein kinase PKR vaccinia virus E3: role complex
                                              formation E3 N-terminal domain. Mol. Cell Biol 1998;18:7304â€“7316. [PubMed: 9819417]
                                          57. Saunders LR, Barber GN. dsRNA binding protein family: critical roles, diverse cellular functions.
                                              FASEB J 2003;17:961â€“983. [PubMed: 12773480]



                                              Ann N Y Acad Sci. Author manuscript; available PMC 2006 17.
                            Zheng et al.                                                                                                    Page 11


                                          58. Scadden AD, Smith CW. RNAi antagonized - hyper-editing. EMBO Rep 2001;2:1107â€“
                                              1111. [PubMed: 11743024]
                                          59. Sharp TV, Moonan F, Romashko  Joshi B, Barber GN, Jagus R. vaccinia virus E3L gene
NIH-PA Author Manuscript




                                              product interacts regulatory substrate binding regions PKR: implications                                               PKR autoregulation. Virology 1998;250:302â€“315. [PubMed: 9792841]
                                          60. Sledz CA, Holko M, Veer MJ, Silverman RH, Williams BR. Activation interferon                                               short-interfering RNAs. Nat. Cell Biol 2003;5:834â€“839. [PubMed: 12942087]
                                          61. Soldan SS, Plassmeyer ML, Matukonis MK, Gonzalez-Scarano F. La Crosse virus nonstructural
                                              protein NSs counteracts effects short interfering RNA. J. Virol 2005;79:234â€“244. [PubMed:
                                              15596819]
                                          62. Stefl R, Skrisovska L, Allain FH. RNA sequence- shape-dependent recognition proteins                                               ribonucleoprotein particle. EMBO Rep 2005;6:33â€“38. [PubMed: 15643449]
                                          63. Strijker R, Fritz DT, Levinson AD. Adenovirus VAI-RNA regulates gene expression controlling
                                              stability ribosome-bound RNAs. EMBO J 1989;8:2669â€“2675. [PubMed: 2583126]
                                          64. Svensson C, Akusjarvi G. novel effect adenovirus VA RNA1 cytoplasmic mRNA abundance.
                                              Virology 1990;174:613â€“617. [PubMed: 2106186]
                                          65. Thimmappaya B, Weinberger C, Schneider RJ, Shenk T. Adenovirus VAI RNA required                                               efficient translation viral mRNAs late times infection. Cell 1982;31:543â€“551. [PubMed:
                                              6297772]
                                          66. Tompkins SM, Lo CY, Tumpey TM, Epstein SL. Protection lethal influenza virus challenge
                                              RNA interference vivo. Proc. Natl. Acad. Sci. U. S. 2004;101:8682â€“8686. [PubMed:
NIH-PA Author Manuscript




                                              15173583]
                                          67. Tonkin LA, Bass BL. Mutations RNAi rescue aberrant chemotaxis ADAR mutants. Science
                                              2003;302:1725. [PubMed: 14657490]
                                          68. Voinnet O. Induction suppression RNA silencing: insights viral infections. Nat. Rev.
                                              Genet 2005;6:206â€“220. [PubMed: 15703763]
                                          69. Volpe TA, Kidner C, Hall IM, Teng G, Grewal SI, Martienssen RA. Regulation heterochromatic
                                              silencing histone H3 lysine-9 methylation RNAi. Science 2002;297:1833â€“1837. [PubMed:
                                              12193640]
                                          70. Wu HL, Huang LR, Huang CC, Lai HL, Liu CJ, Huang YT, Hsu YW, Lu CY, Chen DS, Chen PJ.
                                              RNA interference-mediated control hepatitis B virus emergence resistant mutant.
                                              Gastroenterology 2005;128:708â€“716. [PubMed: 15765406]
                                          71. Yang W, Wang Q, Howell KL, Lee JT, Cho DS, Murray JM, Nishikura K. ADAR1 RNA deaminase
                                              limits short interfering RNA efficacy mammalian cells. J. Biol. Chem 2005;280:3946â€“3953.
                                              [PubMed: 15556947]
                                          72. Zamore PD. Plant RNAi: viral silencing suppressor inactivates siRNA. Curr. Biol
                                              2004;14:R198â€“R200. [PubMed: 15028237]
                                          73. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs ATP-dependent
                                              cleavage mRNA 21 23 nucleotide intervals. Cell 2000;101:25â€“33. [PubMed: 10778853]
NIH-PA Author Manuscript




                                          74. Zeng Y, Yi R, Cullen BR. MicroRNAs small interfering RNAs inhibit mRNA expression                                               similar mechanisms. Proc. Natl. Acad. Sci. U. S. 2003;100:9779â€“9784. [PubMed: 12902540]
                                          75. Zhang H, Kolb FA, Brondani V, Billy E, Filipowicz W. Human Dicer preferentially cleaves dsRNAs
                                              termini requirement ATP. EMBO J 2002;21:5875â€“5885. [PubMed: 12411505]
                                          76. Zheng X, Bevilacqua PC. Activation protein kinase PKR short double-stranded RNAs                                               single-stranded tails. RNA 2004;10:1934â€“1945. [PubMed: 15547138]




                                              Ann N Y Acad Sci. Author manuscript; available PMC 2006 17.
                            Zheng et al.                                                                                             Page 12
NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                          Fig. 1.
                                          RNAi mediated synthetic siRNA duplexes depends active cell growth. Efficiencies                                           synthetic p53 siRNA non-specific (NS) siRNA duplexes cellular p53 expression                                           assayed CaSki cells 2 Ã— 105 20-24 hours (0 time) plating transient transfection
                                          using oligofactamine (Invitrogen). Cell samples prepared 24, 48, 72, 96, 120
                                          hours transfection siRNA (20 nM) diagramed examined Western
                                          blot p53 using anti-p53 antibody (Oncogene). Cells (lane 7) (lane 6) 
                                          transfection NS p53 siRNAs 96 hours initial siRNA transfection,                                           indicated diagram  compared showed difference responding
                                          p53 siRNAs 120 h post initial transfection.




                                              Ann N Y Acad Sci. Author manuscript; available PMC 2006 17.
                            Zheng et al.                                                                                     Page 13
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                          Fig. 2.
                                          RNAi pathways RNAi resistance. Despite different origins, siRNA                                           microRNA similar effects mRNA expression RISC-mediated activities.
                                          Development RNAi resistance mammalian cells possible blocks
                                          (-) RNAi pathways.
NIH-PA Author Manuscript




                                              Ann N Y Acad Sci. Author manuscript; available PMC 2006 17.
                                 Zheng et al.                                                                                                   Page 14

                                                                                             Table 1.
                                Mechanisms development resistance RNAi mammalian cells

                           RNAi-resistance                       Mutation target           Production suppressors   Cellular proteins
                                                                          regions
NIH-PA Author Manuscript




                           RNA viruses
                           Poliovirus                                        Yes
                           HIV-1                                             Yes
                           La Crosse                                         Yes                               NSs
                           PFV-1                                                                               Tas
                           Influenza                                